Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Metastatic × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 61 Lymphoma, Large B-Cell, Diffuse 46 Neoplasms 39 Multiple Myeloma 38 Lymphoma, Non-Hodgkin 37 Lymphoma 34 Recurrence 29 Carcinoma, Non-Small-Cell Lung 29 Lymphoma, Follicular 28 Leukemia, Lymphocytic, Chronic, B-Cell 26 Lymphoma, B-Cell 23 Leukemia, Myeloid, Acute 21 Triple Negative Breast Neoplasms 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Lymphoma, Mantle-Cell 16 Leukemia 15 Pancreatic Neoplasms 12 Ovarian Neoplasms 12 Colorectal Neoplasms 11 Neoplasm Metastasis 10 Melanoma 10 Lymphoma, B-Cell, Marginal Zone 10 Stomach Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Prostatic Neoplasms 8 Lymphoma, T-Cell, Peripheral 8 Liposarcoma, Myxoid 8 Carcinoma, Renal Cell 8 Neutropenia 7 Myelodysplastic Syndromes 7

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡